← Patent-cliff monitor Loss of exclusivity November 2040 latest FDA-listed patent expiry
Company PHARMACOSMOS AS
Drug detail Brand name COSELA Active ingredient TRILACICLIB DIHYDROCHLORIDE Strength EQ 300MG BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval February 2021 Marketing status RX
Listed patents Patent Expires Type 12168666 November 2040 substance, product 11529352 July 2039 use U-3504 12527798 December 2037 use U-3504 8598186 December 2034 substance, product 11717523 March 2034 use U-3679 10966984 March 2034 use U-3080 10085992 March 2034 use U-3081 9487530 March 2034 use U-3080 10189849 October 2031 substance 10927120 October 2031 product 11040042 October 2031 product 9957276 October 2031 substance 8598197 October 2031 substance, product 10189850 October 2031 product
Regulatory exclusivity Code Expires NCE February 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.